Subscribe To
Akari therapeutics to present at emerging growth conference
BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced t...
September 27, 2023, 8:00 am
Immunovant: immune boost, from clinical trials to an aggressive bullish stock
Although Immunovant's stock has rallied around 100% since January, recent data on its therapeutic candidate, IMVT-1402, has further bolstered confiden...
September 27, 2023, 5:30 am
Roivant stock could go higher on monetization potential of ‘blockbuster' assets
Roivant shares finished more than 20% higher on Tuesday after Immunovant, in which Roivant holds a 56.5% stake, released positive data from an early-s...
September 26, 2023, 4:59 pm
Bitcoin gains legal recognition as digital currency in shanghai china
Despite a hostile national policy in China, several courts in the country over the years have recognized bito<...
September 26, 2023, 11:44 am
“kpmg’s report highlighting bitcoin’s positive esg contributions boosts crypto perception”: paybito ceo raj chowdhury
The Paybito chief asserts the global anti-crypto narrative is far from reality. The latest Bitcoin ESG ...
September 26, 2023, 7:14 am
Revolution medicines: a big pipeline in need of big data
Revolution Medicines, Inc. has a diversified pipeline of drugs but is still searching for its flagship project, making it a high-risk investment. The ...
September 25, 2023, 3:24 pm
Zyversa therapeutics announces research published in the journal of clinical investigation reinforcing ic 100’s rationale for inhibiting asc specks to attenuate spread of inflammation into surrounding
Patients with chronic kidney disease (“CKD”) exhibit chronic systemic inflammation characterized by increased circulating levels of IL-1β, IL-6, ...
September 22, 2023, 10:35 am
Inhibikase therapeutics issues a letter to shareholders and comments on recent trading activity
BOSTON and ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmace...
September 20, 2023, 12:30 pm
Poolbeg pharma shores up protection around its ip
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), the clinical-stage biopharmaceutical firm, recently received a notice of allowance from the Japanese Paten...
September 20, 2023, 3:31 am
Acrivon therapeutics to highlight its acr-368 oncosignature test, used in ongoing phase 2 study to treat patients based on predicted sensitivity to monotherapy with its chk1/2 inhibitor acr-368, at th
WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clini...
September 19, 2023, 8:32 pm
Cyteir: although the company is winding down, the lead asset had promise
Cyteir is a developer of cancer therapeutics that has decided to suspend operations and sell all assets. Their lead candidate, CYT-0851, is an MCT1 in...
September 18, 2023, 5:32 pm
Enanta pharmaceuticals to present data for edp-323, its oral, once-daily, l-protein inhibitor in development for the treatment of respiratory syncytial virus, at the 9th eswi influenza conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, sma...
September 17, 2023, 12:00 pm
Exelixis (exel) gets rights for tumor candidate from insilico
Exelixis (EXEL) enters into a license agreement with Insilico Medicine for ISM3091, a potentially best-in-class USP1 inhi...
September 13, 2023, 12:46 pm
Zyversa therapeutics announces research published in frontiers in immunology reinforcing ic 100’s rationale for inhibiting multiple inflammasomes to control inflammation in various inflammatory diseas
Activation of multiple inflammasome pathways contributes to pathological inflammation in neurodegenerative (“CNS”) diseases, such as amyotrophic l...
September 12, 2023, 10:30 am
Exelixis to license insilico ai-designed cancer drug
Exelixis Inc. EXEL, -0.54% is licensing the global rights to develop and commercialize an investigational cancer treatment that was derived from Insil...
September 12, 2023, 8:40 am
Aus gold production tops 80t in june quarter – surbiton
Australian gold production reached 80 t during the three months to June, Melbourne based gold consultants Surb...
September 11, 2023, 6:29 am
Inflarx: small german company targeting a rare indication
InflaRx is a developer of complement mediated therapies for inflammatory diseases. Their lead asset, vilobelimab, is a C5a inhi...
September 6, 2023, 5:31 pm
Curis to present at upcoming healthcare conferences in september
LEXINGTON, Mass. , Sept. 6, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an ora...
September 6, 2023, 8:13 am
Verona pharma to present additional analysis of phase 3 enhance-1 study in copd at ers international congress 2023
Substantial reductions in rate and risk of exacerbations support potential of ensifentrine, an investigational, novel, selective, dual inhi...
September 6, 2023, 2:00 am
Biomea fusion announces appointment of juan pablo frías, m.d. as chief medical officer
Industry veteran and prominent diabetes clinical development expert to oversee Biomea’s progressing clinical development of novel covalent menin inh...
August 31, 2023, 12:30 pm